Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash & Equivalents (2016 - 2026)

Perspective Therapeutics' Cash & Equivalents history spans 17 years, with the latest figure at $270.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 27.96% to $270.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $270.9 million, a 27.96% increase, with the full-year FY2025 number at $30.6 million, down 50.26% from a year prior.
  • Cash & Equivalents hit $270.9 million in Q1 2026 for Perspective Therapeutics, up from $30.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CATX hit a ceiling of $270.9 million in Q1 2026 and a floor of $9.2 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $100.1 million across 5 years, with a median of $55.9 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 1389.18% in 2024 and later plummeted 90.01% in 2025.
  • Tracing CATX's Cash & Equivalents over 5 years: stood at $21.0 million in 2022, then crashed by 55.99% to $9.2 million in 2023, then skyrocketed by 566.59% to $61.6 million in 2024, then tumbled by 50.26% to $30.6 million in 2025, then surged by 784.46% to $270.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for CATX at $270.9 million in Q1 2026, $30.6 million in Q4 2025, and $26.8 million in Q3 2025.